Please try another search
Hexima Limited, a biotechnology company, engages in the research and development of plant-derived proteins and peptides for applications as human therapeutics in Australia. The company’s lead drug candidate is the pezadeftide, which has completed phase II clinical trials for the treatment of onychomycosis. Hexima Limited was incorporated in 1997 and is headquartered in Bundoora, Australia.
Name | Age | Since | Title |
---|---|---|---|
Justin Yap | - | 2018 | Non-Executive Director |
Mark G. Lebwohl | - | - | Member of Scientific Advisory Board |
Phoebe Rich | - | 2021 | Member of the Scientific Advisory Board |
Tracey C. Vlahovic | - | 2021 | Member of the Scientific Advisory Board |
Peter Foley | - | 2021 | Member of the Scientific Advisory Board |
Shari Lipner | - | 2021 | Member of the Scientific Advisory Board |
Warren S. Joseph | - | 2021 | Member of the Scientific Advisory Board |
Geoffrey Paul Kempler | 68 | 2023 | MD & Chairman |
Boni Elizabeth Elewski | - | 2021 | Member of the Scientific Advisory Board |
Shinichi Watanabe | - | 2021 | Member of the Scientific Advisory Board |
Robert Rosen | - | 2021 | Member of the Scientific Advisory Board |
Richard K. Scher | - | 2021 | Member of the Scientific Advisory Board |
Christopher Mews | - | 2023 | Director |
Phillip Hains | - | 2023 | Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review